GRI Bio (GRI) vs Jupiter Neurosciences (JUNS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GRI Bio is the larger company by market cap ($3.8 million vs $3.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | JUNS |
|---|---|---|
| Share price | $1.74 | $2.85 |
| Market cap | $3.80M | $3.76M |
| 1-day change | +3.57% | +2.89% |
| Forward P/E | — | 47.50 |
| EPS (TTM) | $-14.71 | $-18.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $64.12 | $135.75 |
| 52-week low | $1.36 | $2.25 |
| Distance from 52-week high | -97.29% | -97.90% |
| Analyst consensus | none | — |
| Avg. price target upside | +963.22% | — |
| Average volume | 328.24K | 983.10K |
| Shares outstanding | 2.19M | 1.32M |
| Employees | 3 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Jupiter Neurosciences
JUNS stock →Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, engages in the development of therapeutics for central nervous system disorders and rare diseases in the United States and internationally. It operates in two segments, Pharmaceutical Operations and Premium Nutritional Supplements.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
GRI vs JUNS FAQ
Which is bigger, GRI Bio or Jupiter Neurosciences?
GRI Bio (GRI) is larger, with a market capitalization of $3.80M compared with $3.76M for Jupiter Neurosciences (JUNS).
Are GRI Bio and Jupiter Neurosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.